Exploration of novel pyrrolo[2,1-f][1,2,4]triazine derivatives with improved anticancer efficacy as dual inhibitors of c-Met/VEGFR-2

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

F. Michael Yakes, Jason Chen, Jenny Tan et al. · Molecular Cancer Therapeutics · 2011 · 1.3K citations · Full text

Medicine, Oncology, Pharmacology +17

Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer

Manish A. Shah, Zev A. Wainberg, Daniel V.T. Catenacci et al. · PLoS ONE · 2013 · 206 citations · Full text

Medicine, Oncology, Pharmacology +17

Novel Potent Orally Active Selective VEGFR-2 Tyrosine Kinase Inhibitors:  Synthesis, Structure−Activity Relationships, and Antitumor Activities of <i>N</i>-Phenyl-<i>N</i>‘-{4-(4-quinolyloxy)phenyl}ureas

Kazuo Kubo, Toshiyuki Shimizu, Shin-ichi Ohyama et al. · Journal of Medicinal Chemistry · 2005 · 146 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Discovery of Brivanib Alaninate ((<i>S</i>)-((<i>R</i>)-1-(4-(4-Fluoro-2-methyl-1<i>H</i>-indol-5-yloxy)-5-methylpyrrolo[2,1-<i>f</i>][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), A Novel Prodrug of Dual Vascular Endothelial Growth Factor Receptor-2 and Fibroblast Growth Factor Receptor-1 Kinase Inhibitor (BMS-540215)

Zhen‐Wei Cai, Yongzheng Zhang, R. M. Borzilleri et al. · Journal of Medicinal Chemistry · 2008 · 141 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

Discovery and Preclinical Studies of (<i>R</i>)-1-(4-(4-Fluoro-2-methyl-1<i>H</i>-indol-5-yloxy)-5- methylpyrrolo[2,1-<i>f</i>][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an In Vivo Active Potent VEGFR-2 Inhibitor

Rajeev S. Bhide, Zhen‐Wei Cai, Yong‐Zheng Zhang et al. · Journal of Medicinal Chemistry · 2006 · 133 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15